Filing Analysis
Aprea Therapeutics entered into an 'at the market' (ATM) offering agreement with H.C. Wainwright & Co., LLC to sell up to $3.0 million in common stock. The proceeds are intended for general corporate purposes, specifically preclinical studies and clinical trials.
🚩 Red Flags
- Potential dilution for existing shareholders through the ATM offering.
- Small offering size ($3M) relative to typical biotech burn rates may indicate a need for continuous capital infusion.
📋 Key Facts
- Entered into Sales Agreement with H.C. Wainwright & Co., LLC on November 8, 2024.
- Aggregate offering price of up to $3.0 million in common stock.
- Commission rate for the agent is 3.0% of gross proceeds.
- Proceeds earmarked for preclinical studies, clinical trials, and product candidate advancement.
Aprea Therapeutics issued an 8-K to announce its financial results for the third quarter ended September 30, 2024, and provided a corporate presentation update.
📋 Key Facts
- Reported financial results for the three months ended September 30, 2024.
- Released an updated corporate presentation slide deck (Exhibit 99.2).
- Filed under Item 2.02 (Results of Operations and Financial Condition) and Item 8.01 (Other Events).
Aprea Therapeutics announced the presentation of preliminary safety results for its WEE1 inhibitor, APR-1051, at the EORTC-NCI-AACR Symposium in Barcelona.
📋 Key Facts
- Company is presenting preliminary safety results on APR-1051 (WEE1 inhibitor).
- Presentation occurred at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain.
- The disclosure was made via a press release incorporated by reference.
Aprea Therapeutics announced the departure of its Chief Medical Officer, Dr. Nadeem Mirza, effective October 9, 2024, and the appointment of Phillipe Pultar, MD, as Senior Medical Advisor. The company also provided preliminary cash position updates for the quarter ended September 30, 2024.
🚩 Red Flags
- Sequential decrease in cash and cash equivalents (from $28.7M to $26.2M).
- Departure of a key executive (CMO) during the quarterly closing process.
📋 Key Facts
- Dr. Nadeem Mirza is stepping down as Chief Medical Officer effective October 9, 2024.
- Dr. Mirza will remain with the company through at most December 13, 2024, to facilitate transition.
- Phillipe Pultar, MD, has been engaged as Senior Medical Advisor.
- Preliminary cash and cash equivalents expected to be ~$26.2 million as of Sept 30, 2024.
- Cash position decreased from ~$28.7 million on June 30, 2024.
Aprea Therapeutics, Inc. filed an 8-K to announce its quarterly financial results for the period ending June 30, 2024, and updated its corporate presentation slide deck.
📋 Key Facts
- Announced financial results for the three months ended June 30, 2024 via press release (Exhibit 99.1).
- Updated its corporate presentation slide deck as of August 12, 2024 (Exhibit 99.2).
- The filing is categorized under Item 2.02 (Results of Operations and Financial Condition) and Item 8.01 (Other Events).
Aprea Therapeutics held its 2024 annual meeting of stockholders on June 20, 2024. The meeting resulted in the election of three Class II directors and the ratification of EisnerAmper LLP as the company's independent auditor.
📋 Key Facts
- Annual Meeting held on June 20, 2024.
- Quorum reached with 3,826,179 shares (approx. 70.46%) of 5,430,215 total voting shares represented.
- Elected Michael Grissinger, Gabriela Gruia, M.D., and Rifat Pamukcu, M.D. to the Board of Directors for terms ending at the 2027 Annual Meeting.
- Ratified the appointment of EisnerAmper LLP as independent registered public accounting firm for fiscal year 2024 with 3,788,888 votes in favor.
Aprea Therapeutics announced a clinical milestone regarding its oral WEE1 inhibitor, APR-1051. The company has successfully dosed the first patient in the ACESOT-1051 Phase 1 trial.
📋 Key Facts
- First patient was dosed in the ACESOT-1051 Phase 1 clinical trial on June 17, 2024.
- The trial is evaluating APR-1051, an oral WEE1 inhibitor.
- Company updated its corporate presentation slide deck as of June 2024.
Aprea Therapeutics, Inc. filed an 8-K to announce its quarterly financial results for the period ending March 31, 2024 and provided an updated corporate presentation.
📋 Key Facts
- Announced financial results for the three months ended March 31, 2024 via press release (Exhibit 99.1).
- Updated its corporate presentation slide deck as of May 14, 2024 (Exhibit 99.2).
- The filing is categorized under Item 2.02 (Results of Operations and Financial Condition) and Item 8.01 (Other Events).
Aprea Therapeutics issued an 8-K to announce four upcoming poster presentations at the American Association of Cancer Research (AACR) Annual Meeting and provided an updated corporate presentation slide deck.
📋 Key Facts
- Company plans to present four poster presentations at the AACR Annual Meeting.
- Updated corporate presentation slide deck was released on April 10, 2024.
- The filing includes Exhibit 99.1 (Press Release) and Exhibit 99.2 (Corporate Presentation).
Aprea Therapeutics issued an 8-K to announce its financial results for the three and twelve months ended December 31, 2023, and provided a corporate presentation update.
📋 Key Facts
- Announced financial results for the periods ending December 31, 2023 (three and twelve months).
- Released an updated corporate presentation slide deck dated March 2024.
- The filing includes Exhibit 99.1 (Press Release) and Exhibit 99.2 (Corporate Presentation).
Aprea Therapeutics entered into a $16 million private placement agreement to issue common stock and various warrants, while simultaneously terminating an existing at-the-market (ATM) offering with H.C. Wainwright & Co.
🚩 Red Flags
- Significant potential dilution from multiple tranches of warrants (Tranche A and B).
- Termination of a previous ATM offering suggests a shift in financing strategy or preference for this specific private placement.
- Complexity of warrant structures with price-based triggers can lead to volatility.
📋 Key Facts
- Entered into a Securities Purchase Agreement on March 11, 2024.
- Expected aggregate gross proceeds from the private placement: approximately $16.0 million.
- Potential future warrant cash exercise gross proceeds: approximately $18.0 million.
- Issuance of 1,687,712 shares at $7.29 per share.
- Includes Pre-Funded Warrants (up to 507,076 shares), Tranche A Warrants (up to 1,097,394 shares), and Tranche B Warrants (up to 1,097,394 shares).
- Tranche A/B warrants have specific price-based triggers ($14.58 and $18.225 respectively) linked to Phase 2 dose announcements.
- Terminated an existing Sales Agreement with H.C. Wainwright & Co., LLC effective March 11, 2024.
Aprea Therapeutics, Inc. filed an 8-K to announce the update of its corporate presentation slide deck as of February 6, 2024.
📋 Key Facts
- The company updated its corporate presentation slide deck (Exhibit 99.1).
- Filing date: February 6, 2024.
Aprea Therapeutics provided preliminary, unaudited estimates of its cash position as of December 31, 2023. The company reported approximately $21.6 million in total cash, cash equivalents, and restricted cash.
🚩 Red Flags
- Preliminary/unaudited nature of the reported cash position (subject to change).
📋 Key Facts
- Preliminary cash, cash equivalents, and restricted cash balance: ~$21.6 million as of Dec 31, 2023.
- The financial results are unaudited and subject to change upon completion of year-end closing procedures.
- The company is an emerging growth company.
Aprea Therapeutics entered into an 'at the market' (ATM) offering agreement with H.C. Wainwright & Co., LLC to sell up to $1.0 million in common stock. The proceeds are intended for general corporate purposes, specifically preclinical studies and clinical trials.
🚩 Red Flags
- Potential dilution for existing shareholders through the issuance of new common stock.
- Small offering size ($1M) relative to typical biotech burn rates may indicate a need for continuous capital infusions (though not explicitly stated as a going concern).
📋 Key Facts
- Entered into a Sales Agreement with H.C. Wainwright & Co., LLC on January 26, 2024.
- Aggregate offering price of up to $1.0 million in common stock.
- The offering will be conducted via an 'at the market' method pursuant to a Form S-3 registration statement filed on Jan 26, 2024.
- Commission for H.C. Wainwright & Co., LLC is set at 3.0% of gross proceeds.
- Proceeds are earmarked for preclinical studies, clinical trials, and product candidate advancement.
Aprea Therapeutics issued an 8-K to announce a corporate update regarding its development plans for 2024 and released an updated corporate presentation.
📋 Key Facts
- Filed on January 4, 2024.
- Company announced corporate updates and development plans for the year 2024.
- Updated corporate presentation slide deck was released as Exhibit 99.2.